Abstract
The use of hematopoietic stem cell transplant for the treatment of hematological malignancies has continued to grow during the last 10 years. The development of new treatment strategies has minimized the severity and duration of immune suppression after transplantation. This article will review the management and challenges of the most common encountered infections after hematopoietic stem cell transplant. he use of hematopoietic stem cell transplant (HSCT) for the treatment of hematological malignancies has continued to grow during the last 10 years. The development of new treat- ment strategies has minimized the severity and duration of im- mune suppression after transplantation, thus reducing the risk for morbidity and mortality from infectious complications. As our prophylactic measures continue to evolve, resistant organisms emerge representing a challenge for both prevention and treat- ment of infections. Despite the use of screening cultures and pro- phylactic antimicrobials, infections continue to be the primary cause of death in up to 20% of patients after allogeneic stem cell transplantation. This article will review the management and challenges of the most common encountered infections after HSCT.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call